Update on Osteoporosis and Fracture Prevention in Men and Women

This session will provide information regarding the identification of women and men at risk for fracture based on bone densitometry and their 10-year fracture risk using the FRAX calculation. Pharmacologic therapies will be reviewed including patient selection for first line therapies when fracture risk is high and therapies for patients at very high risk including drug risks and benefits. Current controversies will be discussed including long-term use of bisphosphonates, adverse events including osteonecrosis of the jaw (ONJ) and atypical subtrocanteric femur fractures and drug holidays. New concerns about discontinuation of rank ligand inhibitors and the rapid increase in vertebral fractures will be discussed. Treatment of patients at high risk due to therapy such as aromatase inhibitors and androgen deprivation therapy will be presented. Case studies will be used to provide real clinical scenarios.

 *Due to rapidly changing clinical knowledge, once purchased, you have 90 days access to complete this education.

Credits: 1.0 Contact Hours; 0.75 are Pharmacology
Expiration Date: December 31, 2025

$30

LEARNING OBJECTIVES

After taking part in this educational activity, participants should be better able to:

- Discuss the diagnosis of osteoporosis, low bone mass and high and very high risk for fracture

- Discuss current pharmacologic options for fracture prevention

- Discuss controversies in long term management including drug holidays and discontinuation of rank ligand inhibitors

- Discuss appropriate clinical management with case studies

a. Case studies including use of BMD T-scores, FRAX calculation, risks and benefits of pharmacologic therapies

CE INFORMATION

Obtain Your Credits

To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Courses/Certificates' -> 'Transcript/Certificates Earned'  for future access.

Designation Statement

NPACE designates this educational activity for a maximum of 1.0 contact hours, of which 0.75 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.

Accreditation Statement

Nurse Practitioner Associates for Continuing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.

DISCLOSURES

Faculty

Contributing faculty, Nancy Berman, MSN, ANP-BC, MSCP, FAANP has disclosed:

Astellas: Self Advisory Board, Speakers Bureau Non-hormonal treatment of vasomotor symptoms Veozah
Bayer: Spouse Consulting Contraception Essure
Hologic: Spouse Consulting Fibroids Accessa
Organon Consulting Contraception Nexplanon

Planners

All planners and contributors involved in this educational activity have disclosed no relevant financial relationships. 

Disclaimer

The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.

Disclosure of Unlabeled Use

This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

There is no commercial support for this activity.